About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.
This Press release contains and the accompanying conference call will
contain "forward-looking statements" as that term is defined in the Private
Securities Litigation Reform Act of 1995. Words such as, but not limited
to, "look forward to," "believe," "expect," "anticipate," "estimate,"
"intend," "plan," "targets," "likely," "will," "would," "should" and
"could," and similar expressions or words identify forward-looking
statements. Examples of such statements include: (i) statements regarding
the goals, progress and expected timing of clinical studies, including the
progress, timing and design of Phase 3 clinical development for Amigal, the
progress and timing of the availability of data from the Phase 2 extension
study of Amigal, the progress and timing of Phase 2 clinical trials for
Plicera for the treatment of Gaucher disease, the timing of the release of
data from the Phase 2 clinical trials for Plicera, the initiation of Phase
2 clinical development of AT2220 for the treatment of Pompe disease, and
the possibility and timin
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved